Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients (IVIG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02961166|
Recruitment Status : Completed
First Posted : November 10, 2016
Last Update Posted : April 24, 2018
57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.
These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.
|Condition or disease||Intervention/treatment|
|Respiratory Distress Syndrome, Adult Septic Shock||Drug: IgM enriched Immunoglobulins|
57 patients with ARDS requiring ECMO therapy were analyzed retrospectively. 28 patients had received IgM-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy.
Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients.
These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.
|Study Type :||Observational|
|Actual Enrollment :||57 participants|
|Official Title:||Intravenous Immunoglobulin Therapy in ARDS Patients With Extracorporeal Membrane Oxygenation (ECMO) Therapy|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||May 2016|
IgM enriched Immunoglobulins
ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
Drug: IgM enriched Immunoglobulins
Treatment for 3 days
Other Name: Pentaglobin, Biotest Pharma GmbH Germany; Code 170a/90
ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
- Mortality [ Time Frame: during ICU treatment, up to 28 days ]Death during ICU therapy
- lengh of stay (LOS ICU) [ Time Frame: up to 60 days ]lengh of stay on ICU in days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02961166
|University Hospital Tuebingen|
|Tuebingen, Germany, 72076|
|Principal Investigator:||Helene A Haeberle, MD||University Hospital Tuebingen|